The resulting antigen, designated Tc24-C4, showed less aggregation while secondary structure and immunogenicity was not altered, and the production process was found to be suitable for technology transfer in preparation for its production under current Good Manufacturing Practices (cGMP).[17,18] It was further shown in a mouse model that vaccination with Tc24-C4 improved the efficacy of benznidazole treatment and reduced myocarditis and fibrosis during acute T. cruzi infection.[19,20]. The gene discussed is C4A; the disease is myocarditis.